Cytophage Technologies Azioni (OTC: CPTCF)

Ultime notizie per Cytophage Technologies (OTC:CPTCF) Azioni

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.

CYTOPHAGE TECHS INC by CYTOPHAGE TECHNOLOGIES INC

Cytophage Technologies Ltd

Jefferies analyst David Chiaverini initiates coverage on Prosperity Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PB#NYSE">PB</a>) with a Buy rating and announces Price Target of $85.

News

Price Target

Initiation

Analyst Ratings

Jefferies Initiates Coverage On Prosperity Bancshares with Buy Rating, Announces Price Target of $85

In a bold forecast, crypto veteran Fred Krueger has outlined a 90-day macroeconomic chain reaction beginning July 21 that would propel Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) from $150,000 to $600,000 in <a href="https://www.benzinga.com/money/bitcoin-price-prediction">a compressed timeline.</a>
What Happened: In his detailed X <a href="https://x.com/dotkrueger/status/1924839476796522632">post</a> on May 20, Krueger breaks the rise into five accelerating phases, each driven by escalating global crises and institutional shifts toward Bitcoin as a monetary hedge.
Phase 1: Confidence in the Dollar Cracks
The catalyst is a failed $200 billion U.S. Treasury auction, shattering market trust. In this scenario, headlines warn of "no buyers," forcing the Fed to hint at extraordinary interventions.
Simultaneously, BRICS nations unveil a gold- and BTC-based payment system, igniting a rush into hard assets. Within days Bitcoin spikes to $180,000 and Gold rallies to $4,700.
Phase 2: Monetary Panic and Flight to BTC
A major U.S. pension fund collapse accelerates panic. The Federal Reserve implements Yield Curve Control, capping interest rates to contain contagion. But the dollar weakens, and global reserves pivot into Bitcoin.
Tether launches a BTC-backed stablecoin, and Germany backs the euro with 10% gold. 
Bitcoin crosses $265,000, and the DXY falls to 83, signaling a free-fall in dollar confidence. 
Real estate collapses and Treasury yields breach 8.5% before being capped again by the Fed. 
Amid this turmoil, Bitcoin reaches $390,000, and gold approaches $9,000.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45525006/bitcoin-is-about-to-make-a-golden-cross-what-happens-next">Bitcoin Is About To Make A Golden Cross: What Happens Next?</a>
Phase 3: Corporate Adoption and Institutional Pivot
Major U.S. corporations—Apple, Tesla and Google—disclose Bitcoin reserves. Apple stuns markets with a reveal of 200,000 BTC accumulated quietly.
Latin America adopts Bitcoin-based banking systems, and the IMF unveils a new global reserve basket: 50% BTC, dramatically validating Bitcoin's role as global money and Bitcoin spikes to $525,000.
Phase 4: The New Bretton Woods
A global emergency summit in Geneva results in a sweeping monetary reset dubbed the "New Bretton Woods."  
The key outcomes of this are a new U.S. dollar launched, backed 25% by Bitcoin and 25% by gold, alongside the launch of a U.S. CBDC.
The Fed's balance sheet balloons to $44 trillion, oil spikes to $180, and Bitcoin peaks at $600,000. Gold hits $10,400, and the DXY collapses to 68, symbolizing the end of the fiat era and the emergence of Bitcoin as the new global monetary anchor.
Why It Matters: Krueger's thesis, while highly speculative, taps into growing sentiment around declining confidence in fiat currencies, global realignment around hard assets, and the potential for a geopolitical and monetary "black swan" moment that accelerates Bitcoin adoption at scale.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45503054/jack-dorsey-backs-renaming-bitcoins-smallest-unit-bits-calls-satoshi-confusing">Jack Dorsey Backs Renaming Bitcoin&#8217;s Smallest Unit &#8216;Bits,&#8217; Calls &#8216;Satoshi&#8217; Confusing</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin To Hit $600,000 By October? This Wild Scenario Could Make It Happen

On Wednesday, Telomir Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) announced that it had secured $3 million in equity financing through a direct investment by The Bayshore Trust, the company's largest shareholder.
The transaction involved the purchase of 1 million restricted shares of the company's common stock at $3.00 per share, representing an 18% premium to Telomir's closing share price of $2.54 on the execution date.
The transaction was structured as a straight restricted common stock transaction.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44394817/exclusive-telomir-pharmaceuticals-lead-drug-candidate-inhibits-tumor-growth-in-aggressive-prostate-cancer-cells-animal-study-shows" rel="noreferrer noopener">Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows</a>
This transaction follows a prior $1 million equity investment at $7.00 per share made on December 9, 2024, through The Starwood Trust, an entity affiliated with the company's largest shareholder, and complements an existing $5 million non-dilutive line of credit from the same affiliated group, which remains undrawn.
Telomir Chair and CEO Erez Aminov said it had raised $4 million in equity and secured a $5 million credit line through affiliated entities.
Telomir said its priority was to submit its IND by year-end and generate early human efficacy data in the most efficient and capital-responsible way.
Telomir is advancing two highly innovative drug candidates, Telomir-1, a first-in-class age-reversal molecule targeting the root causes of cellular decline, and Telomir-Ag2, a stabilized Silver(II) compound to address the growing threat of drug-resistant infections.
Telomir-1 is an oral small molecule that addresses five fundamental biological drivers of aging and chronic disease: mitochondrial dysfunction, oxidative stress, calcium imbalance, toxic metal accumulation (iron and copper), and telomere shortening.
In preclinical models, Telomir-1 has demonstrated reversal of the biological clock, improving both lifespan and health span, improvement of mitochondrial energy production in metabolically stressed cells, reduction of oxidative stress (ROS), a key contributor to age-related damage, correction of calcium signaling pathways associated with neurodegeneration and cell death, protection against metal-induced toxicity from iron and copper and Telomere lengthening and stabilization to support cellular regeneration.
Telomir-Ag2 is a novel Silver(II) complex stabilized using Telomir's proprietary chelation platform. Silver(II) has historically shown strong antimicrobial potential but has remained clinically impractical due to its instability—until now.
Preclinical studies demonstrated that Telomir-Ag2 is active against Escherichia coli, Pseudomonas aeruginosa, Enterococcus faecalis, Staphylococcus aureus, and Methicillin- and aminoglycoside-resistant Staphylococcus aureus (MARSA).
Price Action: TELO stock closed lower by 10.4% at $2.28 on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/asset-sales/25/05/45522354/intel-eyes-exit-from-networking-and-edge-business-to-refocus-on-pc-data-center-dominance-report" target="_blank" rel="noreferrer noopener">Intel Eyes Exit From Networking And Edge Business To Refocus On PC, Data Center Dominance: Report</a></li>
</ul>

Biotech

Health Care

Financing

Market-Moving Exclusives

Exclusives

TELO

EXCLUSIVE: Telomir Pharma To Raise $3 Million Via Equity Financing To Fund Its Rare Disease IND

EXCLUSIVE: Telomir Tells Benzinga 'The transaction involved the purchase of 1 million restricted shares of the Company's common stock at $3.00 per share, representing an 18% premium to Telomir's closing share price of $2.54 on the date of execution'

EXCLUSIVE: Telomir Pharmaceuticals Tells Benzinga 'Investment from largest shareholder strengthens balance sheet, signals insider conviction, and funds Telomir-1's upcoming IND submission for a rare disease indication'

EXCLUSIVE: Telomir Pharmaceuticals Tells Benzinga Co. Secures $3M At A Premium In Straight Equity Sale Involving No Warrants To Advance Rare Disease IND

Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#CSE">QNTM</a>) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has selected BitGo Trust Company ("BitGo") as one of its partners to securely manage and store its Bitcoin, Solana, XRP and DOGE coin holdings ("crypto currency assets").
BitGo, known for its secure and compliant custody solutions, will provide institutional-grade custody services using its security infrastructure.

CSE:QNTM

QNTM

Quantum BioPharma Selects BitGo to Securely Manage Cryptocurrency Holdings

<a href="https://www.prnewswire.com/news-releases/sk-bioscience-wins-patent-lawsuit-against-pfizer-over-pneumococcal-vaccine-302461472.html" title="https://www.prnewswire.com/news-releases/sk-bioscience-wins-patent-lawsuit-against-pfizer-over-pneumococcal-vaccine-302461472.html">https://www.prnewswire.com/news-releases/sk-bioscience-wins-patent-lawsuit-against-pfizer-over-pneumococcal-vaccine-302461472.html</a>

Legal

Supreme Court Of Korea Rules In SK bioscience's Favor In Patent Infringement Lawsuit Filed Bt Pfizer

Kornit Digital Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNT#NASDAQ">KRNT</a>) ("Kornit" or the "Company"), a global pioneer in sustainable, on-demand digital fashion and textile production technologies, signed a strategic partnership with MAS Holdings via subsidiary MAS ACME USA—a holistic, supply chain orchestration hub, located in North America to serve sustainable fashion and apparel brands. The deal will empower MAS customers, retailers, and brands, to quickly realize the vision of data-driven fashion production and become both more sustainable and profitable.
The commercial agreement directly aligns Kornit with MAS Holdings - a global leader in fashion and sportswear apparel manufacturing, delivering end-to-end supply chain orchestration and operational excellence. MAS is the largest apparel technology company in South Asia, collaborating with brands like Victoria's Secret, PVH, Gap, Marks &amp; Spencer, and Nike.
This agreement formalizes the partners' commitment to building a viable production alternative for an industry plagued by overproduction, unplanned markdowns, and supply chain inefficiencies. Uniting Kornit's digital on-demand production prowess with MAS' supply chain excellence and precision data diagnostics allows brands to avoid missing sales, respond with weekly, US production runs to optimize inventory levels at retail, all while minimizing waste, maximizing full-price sell-through, and freeing up working capital.

KRNT

Kornit Digital Signs Strategic Partnership With MAS Holdings Via Subsidiary MAS ACME USA To Serve Sustainable Fashion And Apparel Brands

Jefferies analyst David Chiaverini initiates coverage on Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) with a Hold rating and announces Price Target of $24.

Jefferies Initiates Coverage On Old National with Hold Rating, Announces Price Target of $24

Based on LAURA Phase III trial results which showed patients who took&nbsp;TAGRISSO after CRT had a median progression-free survival of more than 3 years
MISSISSAUGA, ON, May 21, 2025 /CNW/ - Health Canada has granted a Notice of Compliance with conditions (NOC/c) for Tagrisso&#xAE; (osimertinib) for the treatment of patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during or following platinum based chemoradiation therapy. A validated test is required to identify EGFR mutation-positive status prior to treatment.1
The conditional approval was based on results from the LAURA Phase III trial, which were presented during the Plenary Session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4432011-1&amp;h=2967221920&amp;u=https%3A%2F%2Fwww.nejm.org%2F&amp;a=The+New+England+Journal+of+Medicine">The New England Journal of Medicine</a>.2
Tagrisso&nbsp;reduced the risk of disease progression or death by 84% compared to placebo (hazard ratio 0.16; 95% confidence interval 0.10-0.24; p&lt;0.001) as assessed by blinded independent central review. Median progression-free survival (PFS) was 39.1 months in patients treated with&nbsp;Tagrisso&nbsp;versus 5.6 months for placebo.2&nbsp;Overall survival (OS) results remain immature at this current analysis. The trial continues to assess OS as a secondary endpoint.2
Each year in Canada, 32,000 people are diagnosed with lung cancer3, and 80-85% of these patients are diagnosed with NSCLC, the most common form of lung cancer.4 Approximately 15% of NSCLC patients in Canada have&nbsp;EGFR mutations.5 Nearly one in five people diagnosed with NSCLC has an unresectable&nbsp;tumour.6

Global

General

AstraZeneca Canada Announces Tagrisso Approved In Canada For Patients With Unresectable, Stage III EGFR-Mutated Non-Small Cell Lung Cancer

Waters Acquires Halo Labs, Terms Not Disclosed

DOGE might be slashing roles across federal agencies, but the department itself is on a hiring spree. According to a candidate who recently applied for a position, the hiring process involves a five-stage interview process that takes place over a couple of weeks.
What Happened: The applicant <a href="https://www.wired.com/story/doge-application-interview-process/">told</a> WIRED that the process began with a short screening call, followed by a technical assignment with an immediate deadline. Successful applicants then moved on to two in-depth technical interviews and finally a placement discussion to gauge fit and project alignment. 
According to the applicant, interviewed by the publication, salaries ranged from $120,000 to $190,000, which is in line with top federal pay grades. According to a former USDS insider, this range is not new, but some DOGE recruits with no experience in the public sector are allegedly <a href="https://www.benzinga.com/25/03/44186261/doge-staffers-reportedly-draw-hefty-salaries-funded-by-taxpayers-while-musk-pushes-for-wasteful-spending-cuts">earning as much or more than long-time civil servants</a>.
See Also: <a href="https://www.benzinga.com/news/25/05/45536753/trump-eyes-retirement-overhaul-that-could-push-billions-from-401ks-into-high-stakes-private-equity-funds-report">Trump Eyes Retirement Overhaul That Could Push Billions From 401(k)s Into High-Stakes Private Equity Funds: Report</a>
What to Know: The interviewee was asked to build a basic site to help analyze government regulations. This exercise seems to align closely with DOGE's reported push towards AI-driven deregulation. During the first 15-minute call, a recruiter mentioned some projects DOGE was likely to implement, including, according to the applicant, "leveraging AI to improve medical services for veterans," "streamlining federal aid applications from Americans who experience natural disasters like floods, hurricanes, and tornadoes," and "improving the Free Application for Federal Student Aid (FAFSA) and expanding Americans' access to financial assistance for higher education."
This new insight on DOGE's hiring process comes as controversies surrounding DOGE employees remain unresolved. Two people connected with DOGE were reportedly provided <a href="https://www.benzinga.com/news/25/04/45093187/ex-spacex-intern-and-doge-staffer-gain-access-to-nuclear-security-department-despite-lacking-top-clearance-r">accounts on classified U.S. government networks</a> that manage sensitive nuclear weapons data. A&nbsp;<a href="https://www.benzinga.com/25/04/44859945/whistleblower-alleges-doge-involved-in-major-cybersecurity-breach-at-us-labor-agency" target="_blank" rel="noreferrer noopener">whistleblower report</a>&nbsp;also alleged unauthorized data access at the National Labor Relations Board by DOGE officials.
On Tuesday, <a href="https://www.benzinga.com/media/25/05/45534314/elon-musk-just-got-grilled-on-doge-spending-hits-back-with-were-not-kings-here">Elon Musk, the face of DOGE, responded to questions</a> about its efficacy, saying, "We are advisers. We are not—we&#8217;re not kings here."
Read Next: <a href="https://www.benzinga.com/news/global/25/05/45537805/musks-starlink-could-sidestep-south-african-equity-rules-under-deal-aimed-at-calming-relations-ahead-of-trump-meeting-report">Musk&#8217;s Starlink Could Sidestep South African Equity Rules Under Deal Aimed At Calming Relations Ahead Of Trump Meeting: Report</a>
Photo: Shutterstock

Economics

DOGE Is Hiring Even As It Slashes Federal Jobs—Candidate Reveals A Fast-Paced Five-Step Interview Process With Six-Figure Salaries On The Table

Jefferies analyst David Chiaverini initiates coverage on KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) with a Hold rating and announces Price Target of $18.

Jefferies Initiates Coverage On KeyCorp with Hold Rating, Announces Price Target of $18

<a href="https://pr.report/amzv">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) ("Jaguar" or "the Company"), today announced that it has entered into definitive agreements for the purchase and sale of 246,306 shares of common stock at a purchase price of $6.09 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company agreed to issue to investors unregistered warrants to purchase up to 492,612 shares of common stock at an exercise price of $5.84 per share that will be immediately exercisable upon issuance and will expire on the earlier of (i) 24 months from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event. The closing of the offering is expected to occur on or about May 22, 2025, subject to the satisfaction of customary closing conditions.
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.
The gross proceeds to the Company from the offering are expected to be approximately $1.5 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for general corporate purposes, including growth capital, working capital, operating expenses, repayment of outstanding convertible promissory notes that are not converted into Common Stock by holders, and capital expenditures.

Offerings

JAGX

Jaguar Health Prices $1.5M Registered Direct Offering Of 246,306 Shares At A Price Of $6.09/Share

Jefferies analyst David Chiaverini initiates coverage on First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) with a Buy rating and announces Price Target of $25.

Jefferies Initiates Coverage On First Horizon with Buy Rating, Announces Price Target of $25

While there's simply no denying the remarkable ascent of e-commerce and technology juggernaut Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), even the biggest stalwarts of industry are not completely immune to broader fundamental pressure. As the U.S.<a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45337839/if-you-have-to-google-are-we-in-a-recession-you-probably-feel-like-it"> economy struggles under the weight of elevated inflation</a> and trade tariffs, AMZN stock finds itself caught in a sentiment tug-of-war.
On one hand, analysts can easily argue that the e-commerce behemoth represents the best house in the worst block. While consumers overall may be struggling to make ends meet, Amazon still commands the enviable moat of being the<a href="https://www.benzinga.com/insights/news/25/05/45496882/analyzing-amazon-com-in-comparison-to-competitors-in-broadline-retail-industry"> leading online retailer and marketplace</a> for third-party sellers. True, the company is making inroads into other ventures. However, approximately 75% of Amazon's revenue is tied to its core retail business.
At the same time, the company's Amazon Web Services (AWS) is a profit engine. Furthermore, cloud adoption is rising across various industries. With AWS representing one of the top global cloud brands, Amazon is in an excellent position to grab additional market share. As such, its<a href="https://www.benzinga.com/quote/AMZN"> growth curve</a> can accelerate alongside its profitability metrics.
On the other hand, the trajectory of AMZN stock has been far less impressive in recent sessions as compared to prior years. Since the beginning of January, AMZN is down about 7%. In the past 52 weeks, the equity has only gained about 11%, a rather pedestrian figure that has been eclipsed by the S&amp;P 500.
Financially, a major concern about the mainline e-commerce business is the razor-thin margins. While retail drives the top line, the profit margins are under pressure – a situation that's exacerbated by inflation and tariff threats. Smart money investors also appear to be betting skeptically about AMZN stock, with<a href="https://www.benzinga.com/insights/options/25/05/45519222/a-closer-look-at-amazon-coms-options-market-dynamics"> sentiment recently turning bearish</a> in the options market.
The Direxion ETFs: With AMZN capable of moving sharply in either direction, speculators seeking the possibility of quick profits may consider Direxion's Amazon-focused exchange-traded funds. Specifically, aggressive optimists may consider the Direxion Daily AMZN Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZU#NASDAQ">AMZU</a>), which seeks 200% of the performance of the namesake equity. On the other end, the bears may consider the Direxion Daily AMZN Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZD#NASDAQ">AMZD</a>), which is an inverse fund of AMZN.
Primarily, the utility of the AMZU and AMZD ETFs centers on convenience. Typically, speculators interested in either leveraged wagers or short positions must engage the options market. While derivatives offer incredible flexibility, they can also be complex instruments. With Direxion ETFs, these units can be bought and sold much like any other public security, thus mitigating the learning curve.
Still, prospective investors must be aware of the unique risks of Direxion's leveraged and inverse ETFs. First, these products can be unusually volatile, so caution is warranted. Second, these funds are designed for exposure lasting no longer than one day. Beyond this recommended holding period, investors may incur value decay due to the daily compounding effect.
The AMZU ETF: After starting off the year auspiciously, the Direxion Daily AMZN Bull 2X Shares stumbled under the economic pressure, falling about 23%.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
<ul class="wp-block-list">
<li>With the Trump administration making progress regarding trade policies, AMZU has enjoyed robust near-term momentum, gaining almost 46% in the trailing month.</li>
<li>Currently, AMZU is trading above its 50-day moving average (DMA) but below its 200 DMA. Moving forward, its next natural target is the $35 level.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1030" height="628" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21080949/image-263.png" alt="" class="wp-image-922680" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21080949/image-263.png 1030w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21080949/image-263-300x183.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21080949/image-263-1024x624.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21080949/image-263-768x468.png 768w" sizes="(max-width: 1030px) 100vw, 1030px" /></figure>
The AMZD ETF: Tripping out of the gate, the Direxion Daily AMZN Bear 1X Shares started looking lively later in the year as tariffs spared broader bearishness.
<ul class="wp-block-list">
<li>In contrast to its bullish cousin, the inverse AMZD ETF has struggled in the past month, losing nearly 19% of market value.</li>
<li>At the moment, AMZD finds itself below both its 50 and 200 DMAs. Ideally, the ETF must get above the $13 level soon to avoid serious technical damage.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1030" height="627" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21080949/image-263.png" alt="" class="wp-image-922681" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21080949/image-263.png 1030w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21080949/image-263-300x183.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21080949/image-263-1024x624.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21080949/image-263-768x468.png 768w" sizes="(max-width: 1030px) 100vw, 1030px" /></figure>
Featured image by <a href="https://pixabay.com/users/tungart7-38741244/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=8676517">Tung Lam</a> from <a href="https://pixabay.com/illustrations/e-commerce-shopping-parcels-8676517/">Pixabay</a>

Long Ideas

Short Ideas

Technicals

Trading Ideas

ETFs

AMZD

AMZN

AMZU

An Economic Crossroads Puts Direxion's AMZN-Focused Bull And Bear Funds In The Spotlight

<ul>
<li>Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test</li>
</ul>
Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>), a leading precision oncology company, today announced the addition of a full suite of immunohistochemistry (IHC) testing to the company's portfolio of tumor molecular profiling tests. This new set of tests will help oncologists identify tumor subtypes and match cancer patients to the most effective targeted therapies.
IHC testing is a special staining process that detects specific proteins within a tissue sample, known as tumor biomarkers, that can be used to determine the characteristics of a tumor and identify the most appropriate targeted cancer therapy. The new Guardant IHC test suite provides comprehensive testing for key biomarkers in all solid tumors (such as lung, breast, gastric and ovarian cancers). This includes c-MET, the target of Emrelis&#x2122; (telisotuzumab vedotin-tllv), an antibody-drug conjugate recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of c-MET-expressing non-squamous non-small cell lung cancer (NSCLC).
The comprehensive IHC menu covers the following biomarkers: HER2, MMR, PD-L1, c-MET, ER, PR, Ki-67, CLDN18, and FOLR1.

Guardant Health Adds Full Suite Of Immunohistochemistry Testing To Portfolio Of Tumor Molecular Profiling Tests

Jefferies analyst David Chiaverini initiates coverage on First Foundation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FFWM#NYSE">FFWM</a>) with a Buy rating and announces Price Target of $7.

FFWM

Jefferies Initiates Coverage On First Foundation with Buy Rating, Announces Price Target of $7

BancFirst Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANF#NASDAQ">BANF</a>) today announced it has entered into an agreement to acquire American Bank of Oklahoma (ABOK), a privately held community bank headquartered in Collinsville, Oklahoma. ABOK has approximately $385 million in total assets, $280 million in loans, and $320 million in deposits. The transaction is expected to close in the third quarter of 2025, subject to regulatory approvals and customary closing conditions.
David Harlow, CEO of BancFirst Corporation, commented: "Collinsville and Skiatook are thriving communities that continue to experience dynamic growth in&nbsp;Northeastern Oklahoma. We are excited to welcome the American Bank of Oklahoma team&nbsp;and their customers to BancFirst. This acquisition aligns with our continued commitment to serving communities here in our home state."
Teresa Brown, President &amp; CEO of American Bank of Oklahoma, added: "Joining forces with BancFirst represents a great opportunity for our customers and employees to join one of the strongest banks in the country. We share common values and a commitment to local service, and we look forward to the partnership."
American Bank of Oklahoma will operate under its present name until it is merged into BancFirst, which is expected to be in the fourth quarter of 2025. Customers will receive additional information in the coming months to ensure a seamless transition.

BANF

Bancfirst Corporation Enters Into An Agreement To Acquire American Bank Of Oklahoma, Transaction Is Expected To Close In the Third Quarter of 2025. Terms Not Disclosed

Comments

Cytophage Technologies

Notizie

Ultime notizie per Cytophage Technologies (OTC:CPTCF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO